Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours – guidance (TA539)

Source:
National Institute for Health and Care Excellence - NICE
Publisher:
National Institute for Health and Care Excellence
Publication date:
29 August 2018

Abstract

Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours in adults.